Therapeutic antibodies for prostate cancer

IDrugs

Volumn 3, Issue 10, 2000, Pages 1191-1198

  Leveugle, Béatrice ^a   Mann, Dean ^b   Madiyalakan, Ragupathy ^a,c   Noujaim, A A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MARYLAND   (United States)

^c Biostrat Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747501426     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Parker SL, Tong T, Bolden S, Wingo PA: A cancer journal for clinicians. Cancer Stat (1997) 47(1):5-27.
2. Afrin LB, Stuart RK: Medical therapy of prostate cancer. J S C Med Assoc (1994) 90(5):231-6.
3. Lara PN, Meyers FJ: Treatment options in androgen-independent prostate cancer. Cancer Invest (1999) 17(2):137-44.
4. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK: Overview of the clinical development of Rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol (1999) 26(5):66-73.
5. Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol (1999) 26(4):71-7.
6. Farah RA, Clinchy B, Herrera L, Vitetta ES: The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryotic Gene Expr (1998) 8(3-4):321-56.
7. Weiner LM: Monoclonal antibody therapy of cancer. Semin Oncol (1999) 26(4):43-51.
8. Hudson PJ: Recombinant antibody constructs in cancer therapy. Curr Opin Immunol (1999) 11(5):548-57.
9. Brawer MK: Prostate specific antigen - A review. Acta Oncol (1991) 30(2):161-8.
10. Ablin RJ: A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol (1997) 123(11-12):583-94.
11. Diamandis EP, Yu H: Nonprostatic sources of prostate-specific antigen. Urol Clin North Am (1997) 24(2):275-82.
12. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1987) 7(5B):927-35.
13. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 3(1):81-5.
14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 52(4):637-40.
15. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 48(2):326-34.
16. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (1998) 82(11):2256-61.
17. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 57(17):3629-34.
18. Troyer JK, ML Beckett, GL Wright: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer (1995) 62(5):552-8.
19. Fair WR, Israeli RS, Heston WD: Prostate-specific membrane antigen. Prostate (1997) 32(2):140-8.
20. Su SL, Huang IP, Fair WR, Powell CT, Heston WD: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 55(7):1441-3.
21. O'Keefe DS, Backich DJ, Heston WDW: Cloning and characterization of the prostate-specific membrane antigen-like gene. Proc Am Assoc Cancer Res (2000) 41:39.
22. Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P: TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol (1995) 153(5):1575-9.
23. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res (1998) 4(2):295-302.
24. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks G, Mendelsohn J, Cordon-Cardo C: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res (1995) 1(5):545-50.
25. Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, Van der Kwast TH, Chopin TK: Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol (1998) 29(9):1005-12.
26. Leav I, McNeal JE, Ziar J, Alroy J: The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions. Hum Pathol (1998) 29(7):668-75.
27. Ross JS, JA Fletcher: The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol (1999) 9(2):125-38.
28. Fournier G, Latil A, Amet Y, Abalain JH, Volant A, Mangin P, Floch HH, Lidereau R: Gene amplifications in advanced-stage human prostate cancer. Urol Res (1995) 22(6):343-7.
29. Mark HF, Feldman D, Das S, Kye H, Mark S, Sun CL, Samy M: Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol (1999) 66(2):170-8.
30. Kuhn EJ, Kumot RA, Sesterhenn LA, Chang EH, Moul JW: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol (1993) 150(5):1427-33.
31. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HA: Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer (1993) 72(10):3020-8.
32. Ware JL, Maygarden SJ, Koontz WW, Strom SC: Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol (1991) 22(3):254-8.
33. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A (1999) 96(10):5458-63.
34. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 5(3):280-5.
35. Schultes BC, Zhang C, Xue LY, Noujaim AA, Madiyalakan R: Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model. Hybridoma (1999) 18(1):47-55.
36. Ma J, Samuel J, Kwon GS, Noujaim AA, Madiyalakan R: Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres. Cancer Immunol Immunother (1998) 47(1):13-20.
37. Madiyalakan R, Yang R, Schultes BC, Baum RP, Noujaim AA: OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Hybridoma (1997) 16(1):41-5.
38. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum, Hor G, Noujaim AA: Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma (1995) 14(2):199-203.
39. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA et al: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (1994) 73(3 Suppl):1121-5.
40. Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R: Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother (1998) 46(4):201-12.
41. Hamano Y, Arase H, Saisho H, Saito T: Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol (2000) 164(12):6113-6119.
42. Heyman B: Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol (2000) 18:709-737.
43. Baiu DC, Prechl J, Tchorbanov A, Molina HD, Erdei A, Sulica A, Capel PJ, Hazenbos WL: Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. J Immunol (1999) 162(6):3125-30.
44. Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli, Wardwell K, Howell AL: Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother (1997) 45(3-4):146-8.
45. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S: Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 189(2):371-80.
46. Xue BH, Zhang Y, Sosman JA, Peace DJ: Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate (1997) 30(2):73-8.
47. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY: In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 89(4):293-300.
48. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY: Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol (1998) 161(6):3186-94.
49. Sokoll LJ, Chan CW: Prostate-specific antigen. Its discovery and biochemical characteristics. Urol Clin North Am (1997) 24(2):253-9.
50. Webber MM, Waghray A, Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res (1995) 1(10):1089-94.
51. Leveugle B, Djafargholi N, Zhou F, Kreutz F, Madiyalakan R, Noujaim AA: PSA-directed immunotherapy of prostate cancer. Proc Am Assoc Cancer Res (1998) 89(New Orleans) Abs 2424.
52. Jerne NK: Idiotypic networks and other preconceived ideas. Immunol Rev (1984) 79:5-24.
53. Deo YM, Graziano RF, Repp R, van de Winkel JG: Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today (1997) 18(3):127-35.
54. Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ: Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2′-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res (1999) 19(2A):893-902.
55. Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, Gleason DF: Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Anat Rec (1996) 245(4):652-61.
56. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK: Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol (1999) 162(4):1322-8.
57. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer (1999) 85(7):1586-92.
58. 90Y-CYT-356 monoclonal antibody. Clin Cancer Res (1996) 2(8):1289-97.
59. Maraj BH, Whelan P, Markham AF: Prostate-specific membrane antigen. Br J Urol (1998) 81(4):523-8.
60. Prostate Cancer - Part IV Novel treatment approaches in development. Future Oncol (1998) 4(3/4):830-862.
61. Sundarapandiyan K, Deo YM, Hudson D, Graziano RF: Bispecific antibody-mediated destruction of prostate cancer cells. Proc Am Assoc Cancer Res (2000) 91(San Franscisco): Abs 1837.
62. 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res (1998) 4(3):643-51.
63. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res (1999) 5(10):3254s-3258s.
64. Russoniello C, Somasundaram C, Schlom J, Deo YM, Keler T: Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. Clin Cancer Res (1998) 4(9):2237-43.
65. Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH: Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma (1995) 14(5):461-73.
66. Santos AD, Kashmiri SV, Hand PH, Schlom J, Padlan EA: Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Cancer Res (1999) 5(10):3118s-3123s.
67. McGuinness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG: Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther (1999) 10(2):165-73.
68. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol (1996) 19(6):419-27.
69. Yang X-D, X-C Jia, Corvalan JRF, Wang P, Wu E, Davis CG: Inhibition of cancer growth by ABX-EGF, a fully human anti-EGF receptor monoclonal antibody. Proc Am Assoc Cancer Res (2000) 91(San Fransisco): Abs 3380.
70. Agus DB, Scher HI, Higgins B, Fox, Heller G, Fazzari M, Cordon-Cardo C, Golde DW: Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and - independent human xenograft models. Cancer Res (1999) 59(19):4761-4.
71. Skrepnik N, Zieske AW, Bravo JC, Gillespie AT, Hunt JD: Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts. J Urol (1999) 161(3):984-9.
72. Curnow RT: Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother (1997) 45(3-4):210-5.
73. Odaert B, Jean F, Boutillon C, Buisine E, Melnyk O, Tartar A, Lippens G: Synthesis, folding, and structure of the beta-turn mimic modified B1 domain of streptococcal protein G. Protein Sci (1999) 8(12):2773-83.
74. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate (1998) 35(1):1-10.
75. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldbaus AL, Greenberg NM, Burg MB, Allison JP, Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 94(15):8099-103.
76. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB: Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 96(26):15074-9.
77. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP: Combination immunotherapy of primary prostate cancer in transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 60(9):2444-2448.
78. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res (1997) 3(12):2703-7.
79. 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res (1997) 3(9):1547-55.